Needham analyst Joseph Stringer reiterated a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $70.00. The company’s shares closed last Thursday at $47.95.
According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.0% and a 27.9% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Rhythm Pharmaceuticals.
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $72.33.
See the top stocks recommended by analysts >>
The company has a one-year high of $73.00 and a one-year low of $27.50. Currently, Apellis Pharmaceuticals has an average volume of 1.09M.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Read More on APLS:
